ATE525073T1 - Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten - Google Patents

Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten

Info

Publication number: ATE525073T1
Authority: AT; Austria
Prior art keywords: modulation; tie; treatment; kinase activity; pyrimidylaminobensamides
Prior art date: 2005-01-28

Application number

AT06706432T

Other languages

English (en)

Inventor

Paul W Manley

Georg Martiny-Baron

Juergen Mestan

Original Assignee

Novartis Ag

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-28

Filing date

2006-01-26

Publication date

2011-10-15

2006-01-26 Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag

2011-10-15 Application granted granted Critical

2011-10-15 Publication of ATE525073T1 publication Critical patent/ATE525073T1/de

Links

230000000694 effects Effects 0.000 title abstract 4
201000010099 disease Diseases 0.000 title abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
238000011282 treatment Methods 0.000 title abstract 2
102100022014 Angiopoietin-1 receptor Human genes 0.000 title 1
101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 title 1
101100481410 Mus musculus Tek gene Proteins 0.000 abstract 2
201000003793 Myelodysplastic syndrome Diseases 0.000 abstract 1
108091000080 Phosphotransferase Proteins 0.000 abstract 1
102000001253 Protein Kinase Human genes 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
238000009109 curative therapy Methods 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
208000032839 leukemia Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
102000020233 phosphotransferase Human genes 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
108060006633 protein kinase Proteins 0.000 abstract 1
208000002815 pulmonary hypertension Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Hematology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Dermatology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Child & Adolescent Psychology (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)

AT06706432T 2005-01-28 2006-01-26 Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten ATE525073T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US64789505P	2005-01-28	2005-01-28
US66240405P	2005-03-16	2005-03-16
PCT/EP2006/000686 WO2006079539A2 (en)	2005-01-28	2006-01-26	Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity

Publications (1)

Publication Number	Publication Date
ATE525073T1 true ATE525073T1 (de)	2011-10-15

Family

ID=36273382

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06706432T ATE525073T1 (de)	2005-01-28	2006-01-26	Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten

Country Status (17)

Country	Link
US (1)	US20080114001A1 (de)
EP (1)	EP1843771B1 (de)
JP (2)	JP5373288B2 (de)
KR (2)	KR20130100371A (de)
CN (1)	CN101203224B (de)
AT (1)	ATE525073T1 (de)
AU (1)	AU2006208638B2 (de)
BR (1)	BRPI0606872A2 (de)
CA (1)	CA2594687C (de)
CY (1)	CY1112568T1 (de)
DK (1)	DK1843771T3 (de)
ES (1)	ES2373912T3 (de)
MX (1)	MX2007009135A (de)
PL (1)	PL1843771T3 (de)
PT (1)	PT1843771E (de)
RU (1)	RU2404776C2 (de)
WO (1)	WO2006079539A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007065898A1 (en) *	2005-12-06	2007-06-14	Novartis Ag	Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
JP2009537606A (ja)	2006-05-25	2009-10-29	ノバルティスアクチエンゲゼルシャフト	チロシンキナーゼ阻害剤
EP1923053A1 (de) *	2006-09-27	2008-05-21	Novartis AG	Pharmazeutische Zusammensetzung umfassend Nilotinib oder dessen Salz
TWI433677B (zh)	2007-06-04	2014-04-11	Avila Therapeutics Inc	雜環化合物及其用途
KR20110053354A (ko) *	2008-08-13	2011-05-20	노파르티스 아게	폐동맥 고혈압의 치료
US9207782B2 (en)	2010-12-16	2015-12-08	Lg Electronics Inc.	Remote controller, remote controlling method and display system having the same
CA3137138A1 (en) *	2019-04-18	2020-10-22	EyePoint Pharmaceuticals, Inc.	Methods of treating hypertension with activators of tie-2

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT672041E (pt) *	1993-10-01	2002-04-29	Novartis Ag	Derivados da piridina farmacologicamente activos e processos para a sua preparacao
MY129541A (en) *	1996-06-25	2007-04-30	Novartis Ag	Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
AU5179000A (en) *	1999-06-03	2000-12-28	Basf Aktiengesellschaft	Benzothiazinone and benzoxazinone compounds
US20030199525A1 (en) *	2002-03-21	2003-10-23	Hirst Gavin C.	Kinase inhibitors
GB0215676D0 (en) *	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
GB0222514D0 (en) *	2002-09-27	2002-11-06	Novartis Ag	Organic compounds
US20060154936A1 (en) *	2002-10-25	2006-07-13	Lasky Joseph A	Use of n-'5-'4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
US8178570B2 (en) *	2003-04-09	2012-05-15	Exelixis, Inc.	Tie-2 modulators and methods of use
DK1638941T3 (da) *	2003-05-22	2010-10-11	Abbott Lab	Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer
EP1633710A1 (de) *	2003-06-02	2006-03-15	Abbott Laboratories	Isoindolin-1-onverbindungen als kinasehemmer
AR045037A1 (es) *	2003-07-10	2005-10-12	Aventis Pharma Sa	Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
GB0325031D0 (en) *	2003-10-27	2003-12-03	Novartis Ag	Organic compounds

2006
- 2006-01-26 AT AT06706432T patent/ATE525073T1/de active
- 2006-01-26 MX MX2007009135A patent/MX2007009135A/es active IP Right Grant
- 2006-01-26 KR KR1020137019492A patent/KR20130100371A/ko not_active Ceased
- 2006-01-26 CN CN2006800032580A patent/CN101203224B/zh not_active Expired - Fee Related
- 2006-01-26 US US11/815,046 patent/US20080114001A1/en not_active Abandoned
- 2006-01-26 DK DK06706432.9T patent/DK1843771T3/da active
- 2006-01-26 PT PT06706432T patent/PT1843771E/pt unknown
- 2006-01-26 KR KR1020077017223A patent/KR101325424B1/ko not_active Expired - Fee Related
- 2006-01-26 RU RU2007132255/15A patent/RU2404776C2/ru not_active IP Right Cessation
- 2006-01-26 WO PCT/EP2006/000686 patent/WO2006079539A2/en not_active Ceased
- 2006-01-26 AU AU2006208638A patent/AU2006208638B2/en not_active Ceased
- 2006-01-26 JP JP2007552578A patent/JP5373288B2/ja not_active Expired - Fee Related
- 2006-01-26 PL PL06706432T patent/PL1843771T3/pl unknown
- 2006-01-26 ES ES06706432T patent/ES2373912T3/es not_active Expired - Lifetime
- 2006-01-26 EP EP06706432A patent/EP1843771B1/de not_active Expired - Lifetime
- 2006-01-26 BR BRPI0606872-3A patent/BRPI0606872A2/pt not_active IP Right Cessation
- 2006-01-26 CA CA2594687A patent/CA2594687C/en not_active Expired - Fee Related
2011
- 2011-11-24 CY CY20111101146T patent/CY1112568T1/el unknown
2013
- 2013-07-04 JP JP2013140891A patent/JP2013213042A/ja active Pending

Also Published As

Publication number	Publication date
EP1843771B1 (de)	2011-09-21
CA2594687A1 (en)	2006-08-03
CN101203224B (zh)	2010-11-03
KR101325424B1 (ko)	2013-11-04
AU2006208638A1 (en)	2006-08-03
CA2594687C (en)	2013-10-29
PL1843771T3 (pl)	2012-02-29
WO2006079539A2 (en)	2006-08-03
WO2006079539A3 (en)	2007-11-29
AU2006208638B2 (en)	2010-03-04
BRPI0606872A2 (pt)	2009-07-21
MX2007009135A (es)	2007-09-06
US20080114001A1 (en)	2008-05-15
JP5373288B2 (ja)	2013-12-18
CY1112568T1 (el)	2016-02-10
DK1843771T3 (da)	2012-01-16
JP2008528531A (ja)	2008-07-31
KR20130100371A (ko)	2013-09-10
EP1843771A2 (de)	2007-10-17
PT1843771E (pt)	2011-12-02
CN101203224A (zh)	2008-06-18
KR20070104567A (ko)	2007-10-26
JP2013213042A (ja)	2013-10-17
RU2404776C2 (ru)	2010-11-27
RU2007132255A (ru)	2009-03-10
ES2373912T3 (es)	2012-02-10

Legal Events

Date

Code

Title

Description

2012-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1843771

Country of ref document: EP

Publication	Publication Date	Title
EA200900779A1 (ru)	2010-02-26	Производные дигидропиридина, полезные как ингибиторы протеинкиназы
NO20081454L (no)	2008-04-22	Met-kinaseinhibitorer
EA200700851A1 (ru)	2007-12-28	Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
DE602005015862D1 (de)	2009-09-17	Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien
DE60303238D1 (de)	2006-04-06	Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE478082T1 (de)	2010-09-15	Phosphonate, monophosphonamidate, bisphosphonamidate zur behandlung von virenerkrankungen
DE602005007717D1 (de)	2008-08-07	Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE406351T1 (de)	2008-09-15	Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
DE602005005810D1 (de)	2008-05-15	Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
DE602007010303D1 (de)	2010-12-16	Verwendung von 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen
ATE534633T1 (de)	2011-12-15	Indazolderivate zur behandlung von hsp90- induzierten krankheiten
NO20082096L (no)	2008-05-29	Azaindol-2-karboksamidderivativer
EP1934025A4 (de)	2010-12-01	Zusammensetzung zur behandlung von holz, verfahren zur behandlung von holz und holzprodukt
CY1112568T1 (el)	2016-02-10	Χρηση των πυριμιδυλαμινοβενζαμιδων για τη θεραπεια των νοσων που ανταποκρινονται στην ρυθμιση της δρασης της τιε-2 κινασης
DE602007011398D1 (de)	2011-02-03	Trialkylsilylbenzylaminocarboxyindole, indazole und indoline und ihre verwendung zur behandlung von cetp-vermittelten erkrankungen
ATE542536T1 (de)	2012-02-15	3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen
DE60328603D1 (de)	2009-09-10	Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
ATE548035T1 (de)	2012-03-15	Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
DE602004022035D1 (de)	2009-08-27	Verwendung von pthalide derivativen zur behandlung
ATE504297T1 (de)	2011-04-15	Visnadin zur behandlung von kopfhautjucken
DE60219940D1 (de)	2007-06-14	Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE483460T1 (de)	2010-10-15	Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
TW200726763A (en)	2007-07-16	Novel compound
DE502007006880D1 (de)	2011-05-19	Verwendung von gallium (iii) komplexen zur behandlung von melanomen
ATE439843T1 (de)	2009-09-15	S-mirtazapin zur behandlung von hitzewallungen